Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Chemical Name: 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)(nitroso)amino)-2-methylbenzenesulfonamide
Smiles: CC1=C(S(=O)(N)=O)C=C(N(N=O)C2=NC=CC(N(C)C3=CC4=NN(C)C(C)=C4C=C3)=N2)C=C1
Inchi: InChI=1S/C10H14N6O4/c11-10-13-8(19)7-9(16(10)14-20)15(5-12-7)2-1-6(3-17)4-18/h5-6,17-18H,1-4H2,(H2,11,13,19)
Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping
Yan Li 1, David Q Liu, Shawn Yang, Ravinder Sudini, Michael A McGuire, Dharmesh S Bhanushali, Alireza S Kord
J Pharm Biomed Anal. 2010 Aug 1;52(4):493-507.
Determination and characterization of process impurities in pazopanib hydrochloride drug substance
musty sharada, ravichandra babu
Int J Pharm Pharm Sci, Vol 8, Issue 4, 97-102
Characterization of forced degradation products of pazopanib hydrochloride by UHPLC‐Q‐TOF/MS and in silico toxicity prediction
Prinesh N. Patel Pradipbhai D. Kalariya Mahesh Sharma Prabha Garg M. V. N Kumar Talluri S. Gananadhamu R. Srinivas
Journal of mass spectrometry Volume50, Issue7 July 2015 Pages 918-928
Development and validation of a stability indicating RP-HPLC method for the determination of Pazopanib in bulk drug and its pharmaceutical dosage form
Kishore Kumar Reddy Y, J. Raveendra Reddy and N. Devanna
J. Chem. Pharm. Res., 2015, 7(9):127-132
Validated RP-HPLC Method Development of Pazopanib in Bulk and its Pharmaceutical Dosage Form
Kiran Kumar Buralla, and Varadarajan Parthasarathy
Pharmaceutical Methods,2020,11,1,21-24.
